Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0FEPUX
ADC Name
CN109310885B ADC-7
Synonyms
CN109310885B_ADC-7
   Click to Show/Hide
Organization
Mersana Therapeutics, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Burkitt lymphoma [ICD11:2A85]
Investigative
Drug-to-Antibody Ratio
15-21
Antibody Name
Rituximab
  Antibody Info 
Antigen Name
B-lymphocyte antigen CD20 (MS4A1)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
CN109310885B ADC-7 linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.26
nM
CVCL_0465
Ovarian serous adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
1.83
nM
CVCL_1269
Lung adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
2.76
nM
CVCL_3613
Ovarian clear cell adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
53.04
nM
CVCL_1304
Ovarian endometrioid adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.26 nM Positive CD20 expression (CD20+++/++)
Method Description
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.

   Click to Show/Hide
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.83 nM Positive CD20 expression (CD20+++/++)
Method Description
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.

   Click to Show/Hide
In Vitro Model Lung adenocarcinoma HCC4006 cells CVCL_1269
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 2.76 nM Positive CD20 expression (CD20+++/++)
Method Description
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.

   Click to Show/Hide
In Vitro Model Ovarian clear cell adenocarcinoma TOV-21G cells CVCL_3613
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 53.04 nM Positive CD20 expression (CD20+++/++)
Method Description
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.

   Click to Show/Hide
In Vitro Model Ovarian endometrioid adenocarcinoma IGROV-1 cells CVCL_1304
References
Ref 1 NaPi2b targeting antibody-drug conjugates and methods of use thereof.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.